Q4 2024 EPS Estimates for Mereo BioPharma Group plc Decreased by Leerink Partnrs (NASDAQ:MREO)

Mereo BioPharma Group plc (NASDAQ:MREO) – Analysts at Leerink Partnrs reduced their Q4 2024 EPS estimates for shares of Mereo BioPharma Group in a research note issued to investors on Wednesday, June 19th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of $0.10 per share for the quarter, down from their prior forecast of $0.16. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is $0.03 per share.

Mereo BioPharma Group (NASDAQ:MREO) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.01) EPS for the quarter.

Several other research firms have also recently commented on MREO. Robert W. Baird began coverage on shares of Mereo BioPharma Group in a research note on Thursday, June 13th. They set an “outperform” rating and a $8.00 target price for the company. Baird R W upgraded shares of Mereo BioPharma Group to a “strong-buy” rating in a research note on Thursday, June 13th. SVB Leerink lifted their target price on Mereo BioPharma Group from $6.00 to $8.00 and gave the stock an “outperform” rating in a research report on Thursday, June 20th. Needham & Company LLC upped their price target on Mereo BioPharma Group from $6.00 to $7.00 and gave the company a “buy” rating in a report on Wednesday, June 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a report on Wednesday, June 12th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Mereo BioPharma Group currently has a consensus rating of “Buy” and an average price target of $7.50.

Mereo BioPharma Group Trading Down 5.5 %

Shares of MREO stock opened at $3.76 on Monday. Mereo BioPharma Group has a 12 month low of $1.07 and a 12 month high of $4.50. The stock has a 50 day moving average of $3.26 and a 200-day moving average of $3.17.

Insiders Place Their Bets

In other Mereo BioPharma Group news, insider Alexandra Hughes-Wilson sold 100,432 shares of Mereo BioPharma Group stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $2.97, for a total transaction of $298,283.04. Following the completion of the transaction, the insider now directly owns 32,568 shares of the company’s stock, valued at $96,726.96. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.13% of the company’s stock.

Institutional Investors Weigh In On Mereo BioPharma Group

A number of hedge funds and other institutional investors have recently bought and sold shares of MREO. Rubric Capital Management LP increased its stake in shares of Mereo BioPharma Group by 16.7% in the fourth quarter. Rubric Capital Management LP now owns 13,552,997 shares of the company’s stock valued at $31,307,000 after buying an additional 1,936,877 shares in the last quarter. Rock Springs Capital Management LP lifted its position in shares of Mereo BioPharma Group by 9.0% during the third quarter. Rock Springs Capital Management LP now owns 7,676,481 shares of the company’s stock worth $9,903,000 after purchasing an additional 634,090 shares in the last quarter. 683 Capital Management LLC grew its stake in shares of Mereo BioPharma Group by 11.1% during the third quarter. 683 Capital Management LLC now owns 6,000,000 shares of the company’s stock valued at $7,740,000 after purchasing an additional 600,000 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Mereo BioPharma Group in the first quarter valued at approximately $16,949,000. Finally, Tejara Capital Ltd increased its holdings in shares of Mereo BioPharma Group by 5.8% in the third quarter. Tejara Capital Ltd now owns 3,215,001 shares of the company’s stock valued at $4,147,000 after purchasing an additional 177,030 shares in the last quarter. 62.83% of the stock is owned by institutional investors and hedge funds.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.